What is a Good Sales Multiple For Chemed Corporation (NYSE: CHE)?


Chemed Corporation (NYSE: CHE), a healthcare firm with a market capitalization of $4.8 billion, currently trades at a Sales Multiple of 2.9x which is below the sector’s median multiple of 5.2x. Although this makes CHE look attractive, investors may change their mind after reviewing the assumptions behind the EV / Sales ratio. In the post below, I calculate Chemed Corp’s fair value using a Sales Multiples valuation.

How To Interpret Chemed Corp’s Sales Multiple

A multiples valuation, also known as a comparable companies analysis, determines the value of a subject company by benchmarking the subject’s financial performance against companies deemed to be similar. We can then determine if a company is undervalued or overvalued relative to its peers by comparing metrics like growth, profit margin, and valuation multiples.

EV / Sales, also known as Enterprise Value-to-Sales Multiple or a Sales Multiple, measures the dollars in Enterprise Value for each dollar of revenue. Its key benefit over the P/E multiple is that it’s capital structure-neutral, and, therefore, better at comparing companies with different levels of debt. The general formula behind a Sales Multiples valuation model is the following:

Enterprise Value = Revenue x Selected Multiple

The EV / Sales ratio by itself is not very helpful at all. It is only useful when comparing it to other companies that are considered similar to the subject company. The basic idea is that companies with similar characteristics should trade at similar multiples, all other things being equal. Therefore, we can come to a conclusion about the stock if the ratios are different. In the chart below, I compare Chemed Corp’s EV / Sales ratio to its peer group that includes Civitas Solutions, Inc. (NYSE: CIVI), National HealthCare Corporation (NYSE: NHC), Envision Healthcare Corporation (NYSE: EVHC) and Brookdale Senior Living Inc. (NYSE: BKD).

CHE Sales Multiple vs Peers Chartsource: finbox.io Benchmarks: Sales Multiples

Since Chemed Corp’s EV / Sales ratio of 2.9x is higher than the median of its peers (1.0x), it means that investors are paying more than they should for each dollar of CHE’s revenue. As such, our analysis shows that CHE represents an overvalued stock. Furthermore, finbox.io’s EV / Sales Ratio Model calculates a fair value of $144.60 per share which implies -52.4% downside.

CHE EV / Sales Valuation Calculation

I selected a fair multiple of 1.4x in my analysis by averaging Chemed Corp’s current EV / Sales ratio with its peer group.

Sales Multiple Flaws

While this approach typically provides a reasonable valuation range, it is important to understand that our conclusion rests on some important assumptions. The first being that the selected peer group actually contains companies that truly are similar to Chemed Corp. The second important assumption is that the selected peer group stocks are being fairly valued by the market.

If the assumptions above do not hold to be true, then the difference in EV / Sales ratios could be due to a variety of factors. For example, if you accidentally compare Chemed Corp with lower growth companies, then its sales multiple would naturally be higher than its peers since investors reward high growth stocks with a higher price. Furthermore, sales multiples are highly correlated with EBITDA margins so differences in profit margin often explain differences in valuation.

CHE revenue Growth and Margins vs Peers Tablesource: sales multiples model

Now if the second assumption does not hold true, Chemed Corp’s higher multiple may be because firms in our peer group are being undervalued by the market.

What To Do Next

As a current investor, you may have already conducted fundamental analysis on the company and its stock so its current overvaluation could signal a potential selling opportunity to reduce your exposure to CHE. But keep in mind the EV / Sales ratio’s potential flaws when applying this valuation approach. It is important to note that there are a variety of other fundamental factors that I have not taken into consideration in this article. I highly recommend that you continue your research on Chemed Corp by taking a look at the following:

Valuation Metrics: how much upside do shares of Chemed Corp have based on the Ben Graham Formula? Take a look at our Ben Graham Formula data explorer which also compares the company’s upside to its peers.

Risk Metrics: what is Chemed Corp’s Altman Z score? It’s a famous formula used to predict the probability that a firm will go into bankruptcy within two years. View the company’s Altman Z score here.

Efficiency Metrics: how much free cash flow does Chemed Corp generate as a percentage of total sales? Has it been increasing or decreasing over time? Review the firm’s free cash flow margin here.

As of this writing, I did not hold a position in any of the aforementioned securities and this is not a buy or sell recommendation on any security mentioned.

Expertise: financial technology, analyzing market trends. Brian is a founder at finbox.io, where he’s focused on building tools that make it faster and easier for investors to research stock fundamentals. Brian’s background is in physics & computer science and previously worked as a software engineer at GE Healthcare. He enjoys applying his expertise in technology to help find market trends that impact investors. Brian can be reached at brian@finbox.io or at +1 (516) 778-6257.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.